Evaluation and Validation of the Limited Sampling Strategy of Polymyxin B in Patients with Multidrug-Resistant Gram-Negative Infection

Polymyxin B (PMB) is the final option for treating multidrug-resistant Gram-negative bacterial infections. The acceptable pharmacokinetic/pharmacodynamic target is an area under the concentration–time curve across 24 h at a steady state (AUC(ss,24h)) of 50–100 mg·h/L. The limited sampling strategy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xueyong, Zhang, Bingqing, Cheng, Yu, Chen, Maohua, Lin, Hailing, Huang, Binglin, Que, Wancai, Liu, Maobai, Zhou, Lili, Weng, Qinyong, Zhang, Hui, Qiu, Hongqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698835/
https://www.ncbi.nlm.nih.gov/pubmed/36365141
http://dx.doi.org/10.3390/pharmaceutics14112323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698835/
https://www.ncbi.nlm.nih.gov/pubmed/36365141
http://dx.doi.org/10.3390/pharmaceutics14112323

Ejemplares similares